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Abstract
Introduction: Camellia sinensis belongs to the plant family of Theaceae , native to East Asia, the Indian
Subcontinent and Southeast Asia, but naturalized in many parts of the world. The aim of this study was to
overview its anti-breast cancer chemopreventive and chemotherapeutic effects. This review article is aimed to
overview breast cancer chemopreventive and chemotherapeutic effects of Camellia sinensis (green tea).
Methods: This review article was carried out by searching studies in PubMed, Medline, Web of Science, and
IranMedex databases. The initial search strategy identified around 108 references. In this study, 68 studies were
accepted for further screening, and met all our inclusion criteria [in English, full text, chemopreventive and
chemotherapeutic effects of Camellia sinensis and dated mainly from the year 1999 to 2016. The search terms
were Camellia sinensis, chemopreventive, chemotherapeutic properties, pharmacological effects.
Result: The result of this study suggested that the catechin available in Camellia sinensis has properties which
can prevent and treat breast cancer. It has also been shown to inhibit proliferation of breast cancer cells and to
block carcinogenesis. It was found that increased Camellia sinensis consumption may lower the risk of breast
cancer. Camellia sinensis intake was shown to reduce the risk of breast cancer incidence. In addition, potential
breast cancer chemopreventive effect of Camellia sinensis both in vivo and in vitro was highly confirmed.
However, the evidence of low effect and no effect was observed. More clinical trial studies are needed to prove
its anti-breast cancer activity decisively.
Conclusion: Camellia sinensis is broadly utilized as a part of customary medication since antiquated time
because of its cost adequacy, and fewer reaction properties. The studies demonstrated anti-breast cancer activity
of Camellia sinensis and its component by adjusting cell signaling pathways such as angiogenesis, apoptosis, and
transcription factor. Furthermore, Camellia sinensis and its chemical compound was shown to be extremely
useful in the development of novel anticancer medications.
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1. Introduction
1. Background
The therapeutic role of herbal medicine in the treatment of various diseases, were investigated and confirmed (1-13).
Camellia sinensis belongs to family Theaceae, is indigenous to East Asia and cultivated worldwide in tropical and
subtropical areas. It is a species of hardy shrub, whose leaves and leaf buds are used to make tea. The seeds of
Camellia sinensis are used for therapeutic and cosmetic purposes, and emanate from the leaves of another herb.
Camellia sinensis (green tea) is a Chinese tea, popularly consumed as a healthy beverage, and has been
demonstrated to possess various therapeutic activities, including antioxidants (14-17), anti obesity (18) and
anticancer (19, 20), wound healing (21), cognitive and memory improvement (22),  anti-inflammatory (23), anti
arthritic (24), antibacterial (25), antimicrobial (26, 27), antiangiogenic (28), antiviral (29), cholesterol-lowering
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effects (30) and anti-kidney injury (4). The leaves contribute to cure asthma, angina pectoris, vascular disease, and
diabetes (3, 31). It has been found to possess neuroprotective effect (32). It can also contribute to the treatment of
cardiovascular diseases (33). Camellia sinensis possesses healing effects due to its polyphenol content (34, 35),
especially flavonols. The main constituent of herb is Catechins, which are a sort of polyphenol, and have a
modulatory effect in the various genes in the development and progression of cancer. The major Catechins consist
of: epicatechin (EC), -epicatechin-3-gallate (ECG), epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG)
(36, 37). EGCG is one of the most abundant Catechins containing about 50–80% of the total content of Catechins
(38).
1.2. Statement of problem
There are many medicinal herbs containing natural compositions that have properties which can treat and cure many
diseases. The diversity of natural compounds in herbs and their various roles in preventing and treating different
diseases together with the naturalness and compatibility with the body, and having no adverse effects, motivate
people to have more interest in their application, and researchers to have much more inclination towards studies on
them and recognize their curative effects. However, there is still elusion regarding their efficacy, pharmacological
dosage and toxicity. To achieve this purpose, lots of studies have been carried out to concentrate on the ability of
herbs to generate a favorable chemical and pharmacological profile. Breast cancer is a dangerous and fatal disease.
To cure such a cancer, the intake of a natural agent with no side effects, is of high importance.
1.3. Objective of research
This review article is aimed to overview breast cancer chemopreventive and chemotherapeutic effects of Camellia
sinensis (green tea).
2. Material and Methods
This review was carried out by searching studies in PubMed, Medline, Web of Science, and IranMedex databases.
The initial search strategy identified around 108 references. In this study, 68 studies were accepted for further
screening and met all our inclusion criteria [in English, full text, chemopreventive and chemotherapeutic effects of
Camellia sinensis]. Inclusion criteria were the following key words used to search for the relevant articles published
from 1999 to 2016, their full text should be available in English. Articles included consisted of clinical trials, in
vitro, in vivo, review, or meta-analysis studies. Exclusion criteria were when only abstract was available, not in the
timeline of study. Those articles not matching our inclusion criteria (in other languages than English, between the
timeline of study) were excluded from the study.
3. Results
Increased Camellia sinensis consumption may be inversely associated with risk of breast cancer recurrence.
Furthermore, it showed that this plant is a promising breast cancer chemopreventive candidate via mechanistic
actions of tea polyphenols in growth factor signaling, angiogenesis and lipid metabolism (39). Treatment of 4T1
cells with Camellia sinensis aqueous extract, resulted in significant inhibition of 4T1 cell proliferation via 4T1
apoptosis in a dose-dependent manner. This extract was shown to contribute in bone protection against breast
cancer-induced bone destruction (40). In another study, it was recommended that further clinical trial study with
large sample size on the efficacy of Camellia sinensis polyphenols or extracts are required, before a definitive
decision can be made for its cancer prevention (41). The individual and combined effects of PCB 102 and EGCG on
cell proliferation was evaluated. It was shown that Camellia sinensis which possesses potential chemoprevention of
breast cancer through the process of EGCG, suppressed the proliferation-stimulating activity of the environmental
estrogen PCB 102. Tea or Camellia sinensis drinking was not found to be associated with overall breast cancer risk.
As the result was drawn on pre- and post-menopausal women, it may be interfered (42). In a clinical trial study, the
role of daily Camellia sinensis intake was investigated for 12 months on biomarkers of breast cancer risk. The result
showed a potential anti-breast cancer for green tea (43). In a clinical trial study, GTE on breast cancer biomarkers
was investigated. The result showed that daily intake of GTE is generally well tolerated by a group of mainly
postmenopausal women (44). In a human study of the role of coffee and tea consumption, caffeine intake was
assessed. Findings suggested that coffee and caffeine intake lower the risk of breast cancer, while tea consumption
increased the risk of breast cancer (45). Higher caffeinated coffee intake has lower risk of postmenopausal breast
cancer, while decaffeinated coffee intake does not have any effect on breast cancer (46). Estrogen receptor-
dependent and independent mechanisms are responsible to the treatment of estrogen receptor-positive and estrogen
receptor-negative breast cancer. There was no interaction of herb Catechins with aromatase inhibitors or fulvestrant
(47). Combination of Arc and EGCG with Cur in both cell lines, showed the strongest effects on cell cycle arrest
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and apoptosis increasing chemoprevention in both prostate and breast cancer (48). Camellia sinensis polyphenols
and their applications in the prevention and treatment of breast cancer was investigated. The result showed a
potential effect of Camellia sinensis components on breast cancer (49). Effect of Camellia sinensis in women with
primary breast cancer was assessed. The result showed a decrease in Ki-67 in both benign and malignant cells in the
Camellia sinensis group, confirming its anti- breast cancer activity (50). The relationship between Camellia sinensis
utilization and breast cancer in light of the hormone receptor status of tumors was inspected. No considerable impact
adjustment was seen for menopausal status, 4 SNPs, or dietary consumption of folate or isoflavone. This research
showed that Camellia sinensis intake does not decrease the venture of breast cancer (51). In a Japanese population, it
was found that there was no association between Camellia sinensis intake and risk of breast cancer (52). The
beneficial effect of Camellia sinensis in breast cancer therapy is because of the modification of the breast cancer
miRNA expression profile, as well as the altered miRNA regulation of potential oncogenes and tumor-suppressor
genes (53). In a hormone-resistant breast cancer approach study, the anti-breast cancer effect of Camellia sinensis
extract was attributed to ERα expression restoring by epigenetic mechanisms regulation and HDAC inhibitor
combination (54). The impact of every day utilization of decaffeinated Camellia sinensis for 6 months on weight and
body arrangement, metabolic parameters and lipid profiles in overweight breast growth survivors, was tried.
Consumption of decaffeinated Camellia sinensis for 6 months resulted in reduced weight and improvement in HDL
and glucose homeostasis (55). Suppression of catechol-Omicron-methyltransferases action in human breast
carcinoma cells could expand the proteasome-inhibitory intensity of EGCG and in this way, upgrade its tumor cell
development inhibitory action. COMT inhibition probably expands anti-cancer activity of tea polyphenols, and the
mix may be utilized as a new method or supplementary therapy for breast carcinoma chemotherapy (56).
The effects of EGCG on the migration and invasion of MCF-7 cells was examined. The result illustrated that the
inhibitory effect of EGCG on MCF-7 cell migration and invasion may be caused by a down regulation of VASP
expression through the Rac1 pathway in a concentration-dependent manner (57). Among premenopausal women,
reduced risk was observed for years of Camellia sinensis drinking (P-trend = 0.02), and a dose-response relationship
with the amount of tea consumed per month was also observed (P-trend = 0.046). Thus, the result demonstrated that
Camellia sinensis intake may be loosely associated with a decreased risk of breast cancer (58). In a Chinese
population, higher dietary intake of combination of mushrooms and Camellia sinensis reduced breast cancer risk in
pre- and postmenopausal women (59). There was a protective effect against breast cancer and Camellia sinensis
intake was investigated. The result showed no relationship between Camellia eating and breast cancer venture.
Furthermore, results propose that folate pathway restraint might be one mechanism via which Camellia sinensis
secures against breast cancer (60). The impact of Camellia sinensis Catechins on breast cell carcinogenesis has been
explored. Camellia sinensis Catechins was reported to act in high concentrations or by endocrine treatment (61).
Inhibitory impact of EGCG on stifling tumor angiogenesis and breast cancer advancement was explored. The
findings support the idea that EGCG specifically targets both tumor cells and tumor vasculature, consequently
restraining tumor development, expansion, relocation, and angiogenesis of breast disease (62). The GTC activity at
non-cytotoxic levels was investigated. It was identified that GTC was successful in stifling NNK-and B[a] P-
instigated cell carcinogenesis. GTC might be utilized as a part of dietary and chemoprevention of breast cell
carcinogenesis connected with long haul presentation to low measurements of natural cancer-causing agents (63).
4. Discussion
It is of high importance to identify a healthy lifestyle which will reduce the risk of breast cancer. Although there has
been much progress in its treatment, there is still high a rate of mortality from breast cancer. Medical care
methodologies are needed for chemoprevention of high risk women and for the treatment of receptor negative breast
tumors. In this study, the chemopreventive and chemotherapeutic breast cancer potential of Camellia sinensis was
reviewed. In addition, the mechanisms of action of Camellia sinensis intake against breast cancer was discussed.
Furthermore, the phytochemical property of plant against breast carcinogenesis was overviewed. Several studies
have demonstrated strong chemopreventive and chemotherapeutic actions of Camellia sinensis polyphenols against
cancer. This chemopreventive effect was attributed from one side, to its chemical compound (38) and on the other
side, to its mechanistic action (39, 54, 60, 64, 65). The plant enjoys an anticancer agent partly by regulating
epigenetic processes in ERα silencing in breast cancer lines (54). There are several anti-breast cancer mechanisms of
action of Camellia sinensis. Inhibiting the Folate pathway is the mechanism of cancer preventive activities of EGCG
(60). Another mechanism of action of Camellia sinensis is to inhibit the neoplastic process (62). Green tea extraction
appeared to be compelling in smothering NNK-and B[a] P-incited cell carcinogenesis. GTC might be utilized as a
part of nourishment and chemoprevention of breast cell carcinogenesis (63). All these mechanisms contribute to
prevent and inhibit the cancer processes (initiation, promotion and progress) through the herb uptake. However,
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clinical studies show contradictory results. Many factors possess a serious effect on the ultimate effect of plant
polyphenols on the carcinogenesis process, including the beverage temperature, the period of consumption, and the
amount of consumed tea in proportion to diet (66). Polyphenol, epigallocatechin-3-gallate (EGCG) is the main
chemical compound and an anticancer agent accessible in Camellia sinensis (36). Catechins present in the plant,
hold chemoprevention breast cancer activity via inhibitory impacts of epigallocatechin gallate on the development of
existing tumors consisting breast disease (67). Camellia sinensis polyphenol epigallocatechin gallate (EGCG) and
curcumin (Cur) increases the chemopreventive ability of individual compounds.
5. Conclusions
Camellia sinensis has been widely used in traditional medicine since ancient times due to its cost efficacy, and fewer
side effect properties. The studies demonstrated anti-breast cancer activity of Camellia sinensis and its constituents,
by modulating cell signaling pathways including angiogenesis, apoptosis, and transcription factor. Furthermore,
Camellia sinensis and its chemical compound were shown to be very helpful in the construction of novel anticancer
drugs.
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